Followup recommendations: thyroid cancer, adrenal incidentalomas, and neuroendocrine tumours - Part 6
Malcolm Brigden, MD, FRCPC, FACP; Albert Driedger MD, FRCPC, Irina Rachinsky MD, MSc, FRCPC, and Simron Singh MD, FRCPC
More>>

REVIEW Continuous therapy with lenalidomide in multiple myeloma
Nizar Bahlis, MD
More>>

The Rossy Cancer Network: a philanthropy-driven quality program
Terrence Sullivan, PhD; Tai Huynh, MBA; Armen Aprikian, MD; Gerald Batist, MD; Ann Lynch, Msc; Indrojit Roy, MD; Adalsteinn Brown, DPhil
More>>

REVIEW 40 years of incremental survival improvements in advanced colorectal cancer
Michael Vickers, MD, FRCPC
More>>

 

CT screening for lung cancer: an idea whose time has come?
Daria Manos MD, FRCP
More>>

We welcome your letters and suggestions for future articles.

Please address correspondence to Owen Dyer, Managing Editor, at editors@oncologyex.com

Highlights from ASH 2012 and San Antonio Breast Symposium

Breast cancer: results of Atlas Trial
Debjani Grenier, MD, FRCPC, Medical Oncologist, CancerCare Manitoba
More>>

Results of HERA and Phare Trials
Caroline Lohrisch, MD, FRCPC, Medical Oncologist, Vancouver Cancer Centre; Chair, Breast Cancer Systemic Therapy Committee, BC Cancer Agency
More>>

Non-hodgkin lymphoma: results of the LY12 Study
Douglas Stewart, MD, FRCPC, Chief, Division of Hematology & Hematological Malignancies, University of Calgary. Provincial Leader, Hematology Tumour Team, Alberta Cancer Care
More>>

Mantle cell lymphoma: results of the MCL Younger Trial
Peter Duggan, MD, Clinical Associate Professor, Department of Medicine, University of Calgary. Leader, Tom Baker Cancer Centre Hematology Tumour Group
More>>